Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection (scientific article)

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

Q33877513

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

Q33911935

The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques

Q34124090

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

Q34154514

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

Q34339365

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies

Q34477471

Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development

Q34480617

Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge

Q34574409

IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells

Q34798580

The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses

Q35040673

Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun

Q35066456

Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen

Q35076961

An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum

Q35077677

Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys

Q35077793

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

Q35101333

Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.

Q35165404

The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge

Q35192754

Immunology. Immune activation with HIV vaccines

Q35551760

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

Q35729899

ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses

Q35802771

A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3.

Q35877501

Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens

Q36141515

Risk of immunodeficiency virus infection may increase with vaccine-induced immune response

Q36276637

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

Q36363231

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

Q36403587

Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma

Q36528782

Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production

Q36547664

DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge

Q36637349

IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production

Q36671364

Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques

Q36759774

Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies

Q36760147

T follicular helper cell diversity and plasticity

Q36823844

Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock

Q36827377

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

Q36954239

CD4-induced epitopes in the HIV envelope glycoprotein, gp120.

Q37017799

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

Q37032170

Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

Q37347813

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys

Q37355237

Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein

Q37511699

Qualitative and quantitative variables that affect the potency of Fc- mediated effector function in vitro and in vivo: considerations for passive immunization using non-neutralizing antibodies

Q38160068

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

Q39334333

Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex

Q39593524

Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines

Q40066120

Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques

Q41876895

Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate

Q42054413

Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention

Q42257677

A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques

Q43602552

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid

Q43618512

The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years

Q43818994

Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model

Q43897345

Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100.

Q44551911

Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus

Q45428925

Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin.

Q45722955

Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology

Q45743923

In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein

Q45745791

HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques.

Q51036136

Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.

Q51977322

A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.

Q52841139

Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis

Q54518119

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251

Q64378954

Molecular characterization of SIV in tissues from experimentally infected macaques

Q68589627

Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies

Q72146275

Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity

Q73902433

Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation

Q79213173

A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques

Q80464237

Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses

Q80720967

Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses

Q80973775

Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice

Q81157693

P2507

corrigendum / erratum

Correction for Fouts et al., Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection

Q87132374

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

Macaca

Q177601

P304

page(s)

E992-9

P577

publication date

2015-02-13

P1433

published in

Proceedings of the National Academy of Sciences of the United States of America

Q1146531

P1476

title

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection

P478

volume

112

Reverse relations

cites work (P2860)

Q29365310	2016 International meeting of the Global Virus Network
Q26830360	A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine
Q40748041	An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques
Q38539513	Antibodies as a source of anti-infective peptides: an update
Q64071431	Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection
Q39189458	Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field
Q92538619	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway
Q59352288	Antibody-dependent cellular cytotoxicity in HIV infection
Q90000438	Antibody-dependent cellular cytotoxicity targeting CD4-inducible epitopes predicts mortality in HIV-infected infants
Q54263363	Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay.
Q37497214	Biophysical and Functional Characterization of Rhesus Macaque IgG Subclasses.
Q37261545	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition
Q28084474	Boosting vaccine efficacy the natural (killer) way
Q36008380	Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses
Q92177871	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models
Q90384404	Calcium Phosphate Nanoparticle-Based Vaccines as a Platform for Improvement of HIV-1 Env Antibody Responses by Intrastructural Help
Q35913921	Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1
Q55154648	Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.
Q26782237	Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1
Q58120027	Correlates of GLA family adjuvants' activities
Q53692345	Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors.
Q92019600	Current advances in HIV vaccine preclinical studies using Macaque models
Q55493835	DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response.
Q36071896	Developing a Successful HIV Vaccine
Q38717198	Engineering broadly neutralizing antibodies for HIV prevention and therapy
Q38827936	Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells
Q40040813	Formulation of chitosan with the polyepitope HIV-1 protein candidate vaccine efficiently boosts cellular immune responses in mice
Q95323134	Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help
Q56523156	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14 monocytes is associated with a decreased risk of SIV acquisition
Q41918753	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
Q36323975	HIV-1 gp120 envelope glycoprotein determinants for cytokine burst in human monocytes.
Q40339467	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci
Q59354714	HIV/AIDS Vaccines: 2018
Q26766153	Harnessing the protective potential of HIV-1 neutralizing antibodies
Q55022148	High-resolution definition of humoral immune response correlates of effective immunity against HIV.
Q47215816	Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis.
Q37523341	Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.
Q64234945	Identification of HIV gp41-specific antibodies that mediate killing of infected cells
Q59357079	Immune Correlate-Guided HIV Vaccine Design
Q40071705	Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
Q98196674	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
Q37399606	Impaired T Cell-dependent Humoral Immune Response Associated with Juvenile-onset Recurrent Respiratory Papillomatosis Progression
Q47110966	Increasing the Clinical Potential and Applications of Anti-HIV Antibodies
Q64084496	Induction of Fc-Mediated Effector Functions Against a Stabilized Inner Domain of HIV-1 gp120 Designed to Selectively Harbor the A32 Epitope Region
Q64263004	Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1
Q64066666	Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function
Q92340123	Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo Models
Q104486611	Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4⁺/CD8⁺ T cells and humoral responses in macaques
Q64115950	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response
Q64268432	Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
Q38652858	Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo
Q47112156	Novel Concepts for HIV Vaccine Vector Design
Q40730039	Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region
Q39305961	Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections
Q47109778	Patterns of conserved gp120 epitope presentation on attached HIV-1 virions
Q37718399	Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma.
Q33821896	Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition
Q34540352	Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Q92288781	Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector
Q91276841	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV
Q36523998	Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques
Q36708266	Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine
Q61816156	Structural Basis for Epitopes in the gp120 Cluster A Region that Invokes Potent Effector Cell Activity
Q30238730	Survivors Remorse: antibody-mediated protection against HIV-1.
Q30238729	Systems serology for evaluation of HIV vaccine trials
Q47604797	Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region.
Q64060305	The Antibodiome-Mapping the Humoral Immune Response to HIV
Q42723888	The Toughest Nut to Crack: Will We Ever Have a Preventive and Effective HIV-1 Vaccine?
Q37113972	The role of Fc receptors in HIV prevention and therapy
Q55411165	Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses.
Q91893991	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells
Q60908099	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers
Q40042419	Vector order determines protection against pathogenic simian immunodeficiency virus infection in a triple component vaccine by balancing CD4+ and CD8+ T-cell responses

P819	ADS bibcode	2015PNAS..112E.992F
P356	DOI	10.1073/PNAS.1423669112
P932	PMC publication ID	4352796
P698	PubMed publication ID	25681373
P5875	ResearchGate publication ID	273900348